Loading
TAK-928 is an experimental bispecific antibody from Takeda in phase 3 trials for non-small-cell lung cancer, aimed at PD-1 and CD25 (IL-2 receptor alpha).
TAK-928 is a bispecific antibody developed by Takeda. Its targets are PD-1 and CD25 (IL-2 receptor alpha) (the sponsor names PD-1 x IL-2 receptor (CD25)). The sponsor states: Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion. ClinicalTrials.gov describes the intervention as: TAK-928 will be administered by IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07217301, plans to enrol 600 participants with primary completion expected 2028-11-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion. Connects to PD-1 and CD25 (IL-2 receptor alpha).
1.One arm of TAK-928 binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TAK-928" OR ABSTRACT:"TAK-928") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TAK-928, not a curated reading list.
Shares Takeda, Non-small-cell lung cancer and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares Takeda and the tag pipeline.